Rapt Therapeutics appoints Scott Braunstein, Ashley Dombkowski to board

RAPT Therapeutics (RAPT) announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company’s lead product candidate RPT904, is a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E , a key driver of several allergic diseases. RPT904 is currently completing Phase 2 trials in chronic spontaneous urticaria and asthma, and RAPT plans to initiate a Phase 2 clinical trial for food allergy later this year. Braunstein has been an operating partner at Aisling Capital since 2015. Dombkowski is currently CEO and President of Cellics Therapeutics, a biotechnology company developing novel biologics to address significant unmet medical needs in inflammation and immunology.